Similarly, while the silencing of either ATP13A3 or SLC3A2 in neuroblastoma cells resulted in reduced polyamine uptake, only the silencing of ATP13A3, and not of SLC3A2, was sufficient to prevent the compensatory increase in polyamine uptake under DFMO treatment. Here, SLC3A2 is linked to neuroblastoma.